Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Focus Technologies West Nile testing

This article was originally published in The Gray Sheet

Executive Summary

Herndon, Va.-based firm files 510(k) with FDA for West Nile virus IgM and IgG ELISA diagnostic kits June 25 upon completion of clinical trials. Focus began shipping WNV flavivirus reagents to commercial and public labs in April (1"The Gray Sheet" May 5, 2003, In Brief)...

You may also be interested in...

West Nile Virus: FDA Clears PanBio Test, Canada Okays Roche Blood Screen

The de novo 510(k) route pursued by PanBio for its Capture West Nile virus clinical lab test could set a precedent for expedited approvals of diagnostics to detect emerging diseases

West Nile virus testing

Focus Technologies begins shipments of Flavivirus (WNV) antibody detection reagents to public and commercial labs April 29. Based on protein antigen technology licensed from CDC, the analyte-specific reagent configurations will now be evaluated by major U.S. labs. Ongoing clinical trials at Mayo Clinic and the New York Department of Health will support a 510(k) submission to FDA this summer, and also will determine if the test is sufficiently sensitive to yield conclusive results without plaque reduction neutralization testing (RPNT), currently required for confirmation (1"The Gray Sheet" March 17, 2003, p. 8). In June, Focus will begin offering confirmatory PRNT in its lab as an alternative to public health testing options...

What Lies Ahead: COVID-19 Vaccination Challenges

The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts